365997-32-6 Usage
Description
(1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is a complex organic molecule characterized by its specific stereochemistry and functional groups. It features an ethyl group attached to a 3-azido-4-hydroxycyclohexanecarboxylate moiety, which includes an azido group that is indicative of its potential use in click chemistry and bioconjugation reactions. The hydroxycyclohexanecarboxylate component suggests possible pharmaceutical or medicinal applications, as similar structures are observed in natural products and pharmaceutical compounds. (1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate holds promise for a diverse array of chemical and biological applications due to its unique structure and functionality.
Uses
Used in Pharmaceutical and Medicinal Chemistry:
(1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is used as a precursor in the synthesis of pharmaceutical compounds for its potential medicinal properties. The hydroxycyclohexanecarboxylate moiety, which is similar to structures found in natural products and pharmaceuticals, lends itself to the development of new drugs with therapeutic benefits.
Used in Click Chemistry and Bioconjugation:
(1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is utilized as a reactant in click chemistry for its azido group, which allows for efficient and selective reactions with other molecules. This property is particularly useful in the field of bioconjugation, where it can be employed to attach biologically active molecules to various carriers or probes for research and diagnostic purposes.
Used in Chemical Synthesis:
In the chemical synthesis industry, (1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is used as an intermediate or building block for the creation of more complex organic molecules. Its unique structure and functional groups make it a valuable component in the synthesis of specialty chemicals and materials with specific properties.
Used in Research and Development:
(1S,3R,4R)-ethyl 3-azido-4-hydroxycyclohexanecarboxylate is employed as a research tool in academic and industrial laboratories. Its specific stereochemistry and functional groups make it an interesting subject for studies in organic chemistry, medicinal chemistry, and materials science, where it can be used to explore new reaction pathways, mechanisms, and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 365997-32-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,5,9,9 and 7 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 365997-32:
(8*3)+(7*6)+(6*5)+(5*9)+(4*9)+(3*7)+(2*3)+(1*2)=206
206 % 10 = 6
So 365997-32-6 is a valid CAS Registry Number.
365997-32-6Relevant articles and documents
Stereoselective synthesis and biological evaluation of 3,4-diaminocyclohexanecarboxylic acid derivatives as factor Xa inhibitors
Nagata, Tsutomu,Nagamochi, Masatoshi,Kobayashi, Shozo,Komoriya, Satoshi,Yoshino, Toshiharu,Kanno, Hideyuki
, p. 4587 - 4592 (2008)
There have been few reports on synthetic methods for cis-1,2-diaminocyclohexane bearing a third ring substituent. Starting from 3-cyclohexenecarboxylic acid, we developed efficient methods for synthesizing the 3,4-diaminocyclohexanecarboxylic acid derivat
HETEROARYL COMPOUNDS AND USES THEREOF
-
Page/Page column 290, (2014/09/29)
The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.
2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)
-
Page/Page column 45, (2008/06/13)
The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).
